Dyego L B Souza1,2, Albert Oliveras-Fabregas2,3, Eduard Minobes-Molina2, Marianna de Camargo Cancela4, Paola Galbany-Estragués2, Javier Jerez-Roig5,6. 1. Department of Collective Health, Postgraduate Programme in Collective Health, Federal University of Rio Grande do Norte, Natal, Brazil. 2. Research group on Methodology, Methods, Models and Outcomes of Health and Social Sciences (M3O). Faculty of Health Sciences and Welfare. Centre for Health and Social Care Research (CESS), University of Vic-Central University of Catalonia (UVic-UCC), C. Sagrada Família, 7, 08500, Vic, Spain. 3. Physical Activity, Sport and Health Research Group. Faculty of Psychology, Education and Sport Sciences Blanquerna, Universitat Ramon Llull, Barcelona, Spain. 4. Division of Population Research, Brazilian National Cancer Institute, Rio de Janeiro, Brazil. 5. Department of Collective Health, Postgraduate Programme in Collective Health, Federal University of Rio Grande do Norte, Natal, Brazil. javier.jerez@uvic.cat. 6. Research group on Methodology, Methods, Models and Outcomes of Health and Social Sciences (M3O). Faculty of Health Sciences and Welfare. Centre for Health and Social Care Research (CESS), University of Vic-Central University of Catalonia (UVic-UCC), C. Sagrada Família, 7, 08500, Vic, Spain. javier.jerez@uvic.cat.
Abstract
BACKGROUND: The objective of this work was to analyse the prevalence trends of multimorbidity among European community-dwelling adults. METHODS: A temporal series study based on waves 1, 2, 4, 5, 6 and 7 of the Survey of Health, Ageing and Retirement in Europe (SHARE) was conducted, and community-dwelling participants aged 50+ (n = 274,614) from 15 European countries were selected for the period 2004-2017. Prevalence, adjusted by age, Average Annual Percentage Change (APC) and 95% confidence interval (95% CI) were all calculated. Trend analyses were realised by period, age groups and groups of diseases. RESULTS: The results showed a large variability in the prevalence of multimorbidity in adults aged 50 and over among European countries. Increase in the prevalence of multimorbidity in the countries of central Europe (Austria, Belgium, Czech Republic, France, Germany and Switzerland) and Spain in both sexes, and in the Netherlands among men. Stability was observed in northern and eastern European countries. Musculoskeletal and neurodegenerative groups showed more significant changes in the trend analyses. CONCLUSIONS: This information can be useful for policy makers when planning health promotion and prevention policies addressing modifiable risk factors in health.
BACKGROUND: The objective of this work was to analyse the prevalence trends of multimorbidity among European community-dwelling adults. METHODS: A temporal series study based on waves 1, 2, 4, 5, 6 and 7 of the Survey of Health, Ageing and Retirement in Europe (SHARE) was conducted, and community-dwelling participants aged 50+ (n = 274,614) from 15 European countries were selected for the period 2004-2017. Prevalence, adjusted by age, Average Annual Percentage Change (APC) and 95% confidence interval (95% CI) were all calculated. Trend analyses were realised by period, age groups and groups of diseases. RESULTS: The results showed a large variability in the prevalence of multimorbidity in adults aged 50 and over among European countries. Increase in the prevalence of multimorbidity in the countries of central Europe (Austria, Belgium, Czech Republic, France, Germany and Switzerland) and Spain in both sexes, and in the Netherlands among men. Stability was observed in northern and eastern European countries. Musculoskeletal and neurodegenerative groups showed more significant changes in the trend analyses. CONCLUSIONS: This information can be useful for policy makers when planning health promotion and prevention policies addressing modifiable risk factors in health.
Authors: Jean Yves Le Reste; Patrice Nabbe; Benedicte Manceau; Charilaos Lygidakis; Christa Doerr; Heidrun Lingner; Slawomir Czachowski; Miguel Munoz; Stella Argyriadou; Ana Claveria; Bernard Le Floch; Marie Barais; Peter Bower; Harm Van Marwijk; Paul Van Royen; Claire Lietard Journal: J Am Med Dir Assoc Date: 2013-02-12 Impact factor: 4.669
Authors: Sonia Jean; Marie Hudson; Philippe Gamache; Louis Bessette; Paul R Fortin; Gilles Boire; Sasha Bernatsky Journal: Clin Rheumatol Date: 2017-08-21 Impact factor: 2.980
Authors: Margot A J B Tacken; Wim Opstelten; Ilse Vossen; Ivo J M Smeele; Hilly Calsbeek; J E Annelies Jacobs; Jozé C C Braspenning Journal: Ned Tijdschr Geneeskd Date: 2011
Authors: Petra Hopman; Marianne J Heins; Joke C Korevaar; Mieke Rijken; François G Schellevis Journal: Eur J Intern Med Date: 2016-09-15 Impact factor: 4.487
Authors: Sandra H van Oostrom; Ronald Gijsen; Irina Stirbu; Joke C Korevaar; Francois G Schellevis; H Susan J Picavet; Nancy Hoeymans Journal: PLoS One Date: 2016-08-02 Impact factor: 3.240
Authors: Markus Gnädinger; Lilli Herzig; Alessandro Ceschi; Dieter Conen; Alfred Staehelin; Marco Zoller; Milo A Puhan Journal: Int J Public Health Date: 2018-05-21 Impact factor: 3.380
Authors: Marjorie C Johnston; Michael Crilly; Corri Black; Gordon J Prescott; Stewart W Mercer Journal: Eur J Public Health Date: 2019-02-01 Impact factor: 3.367
Authors: Phuong Bich Tran; Joseph Kazibwe; Georgios F Nikolaidis; Ismo Linnosmaa; Mieke Rijken; Josefien van Olmen Journal: BMC Med Date: 2022-07-19 Impact factor: 11.150
Authors: Anna Nicolet; Dan Assouline; Joachim Marti; Isabelle Peytremann-Bridevaux; Marie-Annick Le Pogam; Clémence Perraudin; Christophe Bagnoud; Joël Wagner Journal: JMIR Med Inform Date: 2022-04-04
Authors: Larissa Virnau; Annett Braesigk; Tobias Deutsch; Alexander Bauer; Eric Sven Kroeber; Markus Bleckwenn; Thomas Frese; Heidrun Lingner Journal: Scand J Prim Health Care Date: 2022-06-30 Impact factor: 3.147
Authors: Lízie Emanuelle Eulálio Brasileiro; Aílla Lorenna de Medeiros Paiva; Maria Yasmin Dantas de Medeiros; Javier Jerez-Roig; Dyego Leandro Bezerra de Souza Journal: BMJ Open Date: 2021-07-20 Impact factor: 2.692